Jump to content

Chlormerodrin

From Wikipedia, the free encyclopedia
(Redirected from Neogidrin)
Chlormerodrin
Names
IUPAC name
3-carbamoylamino-2-methoxypropylmercury(II) chloride
Systematic IUPAC name
3-chloro-mercura-2-methoxy propylurea
Other names
  • Chloromeridin
  • Chlormerodin
  • Chlormerodrine
  • Chlormeroprin
  • Diurone
  • Katonil
  • Mercardox
  • Mercloran
  • Mercoral
  • Merculest
  • Merilid
  • Neogidrin
  • Neohydrin
  • Oricur
  • Percapyl
  • Promeran
  • Promerane
  • 3-chloro-mercuri-2-methoxy propylurea
  • [3-(Carbamoylamino)-2-methoxypropyl](chloro)mercury
Identifiers
3D model (JSmol)
ECHA InfoCard 100.000.483 Edit this at Wikidata
  • COC(CNC(N)=O)C[Hg]Cl
Properties
C5H11ClHgN2O2
Molar mass 367.20 g·mol−1
Appearance Solid
Melting point 152.5 °C (306.5 °F; 425.6 K)
11 g/L
Hazards
Occupational safety and health (OHS/OSH):
Main hazards
Renal mercury poisoning
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Chlormerodrin
Clinical data
AHFS/Drugs.comMedical Encyclopedia
ATC code
  • none
Legal status
Legal status
  • US: Withdrawn
Identifiers
  • 3-carbamoylamino-2-methoxypropylmercury(II) chloride
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
ECHA InfoCard100.000.483 Edit this at Wikidata
Chemical and physical data
FormulaC5H11ClHgN2O2
Molar mass367.20 g·mol−1
3D model (JSmol)
  • COC(CNC(=O)N)C[Hg]Cl
  • InChI=1S/C5H11N2O2.ClH.Hg/c1-4(9-2)3-7-5(6)8;;/h4H,1,3H2,2H3,(H3,6,7,8);1H;/q;;+1/p-1
  • Key:BJFGVYCULWBXKF-UHFFFAOYSA-M

Chlormerodrin is a mercurial diuretic commercially traded from 1952[1] until 1974[2] that was once used to treat patients with heart failure,[3] but is no longer in widespread use.[4] The radiolabelled form (197Hg & 203Hg) had also been used for medical imaging of the kidney and brain[5][6] and the 197Hg form was even considered a contender for 99mTc by some physicians,[7] but was ultimately discontinued by the FDA in 1989.[8]

References

[edit]
  1. ^ Sittig M (1988). Pharmaceutical Manufacturing Encyclopedia. Westwood: Noyes Publications.
  2. ^ Crout JR (1974). "Fixed combination prescription drugs: FDA policy". Journal of Clinical Pharmacology. 14 (5–6): 249–254. doi:10.1002/j.1552-4604.1974.tb02309.x. PMID 4829517. S2CID 5830209.
  3. ^ Leff WA, Nussbaum HE (April 1959). "Chlormerodrin: clinical effectiveness and absence of toxicity in congestive heart failure; report of a four-year study". British Medical Journal. 1 (5126): 883–889. doi:10.1136/bmj.1.5126.883. PMC 1992943. PMID 13629153.
  4. ^ "Chlormerodrin". PubChem. U.S. National Library of Medicine. Retrieved 2021-09-23.
  5. ^ Sodee DB, Di Stefano B (September 1965). "The Clinical Value of Today's Radioisotope Scanning". The Ohio State Medical Journal. 61: 819–22. PMID 14340215.
  6. ^ Yamamoto YL, Feindel W, Zanelli J (September 1964). "Comparative study of radioactive chlormerodrin (Neohydrin) tagged with mercury 197 and mercury 203 for brain scanning". Neurology. 14 (9): 815–820. doi:10.1212/wnl.14.9.815. PMID 14215595. S2CID 43526449.
  7. ^ Sodee DB (December 1968). "Comparison of 99mTc-pertechnetate and 197Hg-chlormerodrin for brain scanning". Journal of Nuclear Medicine. 9 (12): 645. PMID 5729215.
  8. ^ FDA, Approved Drug Products with Therapeutic Equivalence Evaluations, US Department Of Health And Human Service, 1989.